Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Medrx Co. Ltd. currently has 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are spread across 3 distinct examiners, meaning no single examiner is handling more than 1 active case for the company. The portfolio's current activity is also divided among 3 distinct art units, indicating a diverse range of technical review processes across different groups at the patent office.
HASTINGS, ALISON AZAR is the busiest examiner for this portfolio, with 1 busiest examiner pending office action. Since there are 3 distinct examiners for 3 total pending office actions, the workload is distributed among the officials. This structure implies that the company's prosecution efforts are currently decentralized across several different examination groups within the biotechnology sector. For practitioners, this requires managing 3 separate examiner interactions, as each of the 3 pending office actions is being evaluated independently by a different examiner in a different art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HASTINGS, ALISON AZAR | 1 | 63.5% | +40.2% |
| WELLES, COLMAN THOMAS | 1 | 29.2% | +64.2% |
| SOROUSH, LAYLA | 1 | 40.5% | +43.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18852301 | FORMULATION HAVING IMPROVED ABSORBABILITY OF LOW-SOLUBLE AND/OR LOW-MEMBRANE-PERMEABLE DRUG | HASTINGS, ALISON AZAR | — |
| 18276937 | COMPOSITION IN WHICH ABSORBABILITY OF POORLY ABSORBABLE DRUG IS IMPROVED | WELLES, COLMAN THOMAS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18852301 | FORMULATION HAVING IMPROVED ABSORBABILITY OF LOW-SOLUBLE AND/OR LOW-MEMBRANE-PERMEABLE DRUG | HASTINGS, ALISON AZAR | — |
| 18276937 | COMPOSITION IN WHICH ABSORBABILITY OF POORLY ABSORBABLE DRUG IS IMPROVED | WELLES, COLMAN THOMAS | — |
| 17926386 | Transdermal Formulation Containing Apomorphine | SOROUSH, LAYLA | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| 1612 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18852301 | FORMULATION HAVING IMPROVED ABSORBABILITY OF LOW-SOLUBLE AND/OR LOW-MEMBRANE-PERMEABLE DRUG | HASTINGS, ALISON AZAR | 1629 | §102§103 | Non-Final OA | — | Pending | Sep 27, 2024 |
| 18276937 | COMPOSITION IN WHICH ABSORBABILITY OF POORLY ABSORBABLE DRUG IS IMPROVED | WELLES, COLMAN THOMAS | 1612 | §103§112 | Non-Final OA | — | Pending | Aug 11, 2023 |
| 17926386 | Transdermal Formulation Containing Apomorphine | SOROUSH, LAYLA | 1622 | §103 | Final Rejection | — | Pending | Nov 18, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial